SCHEMBL6749604

SCHEMBL6749604

c1ccc2c3c([nH]c2c1)C1(CCNCC1)NCC3

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.76
OPRM1 P35372 6/20 0.64
OGFRL1 Q5TC84 5/20 0.64
OPRL1 P41146 2/20 0.64
KMT2A Q03164 4/20 0.57
CFTR P13569 4/20 0.54
HTR2A P28223 1/20 0.51
HTR2C P28335 1/20 0.51
CDK8 P49336 1/20 0.50
NTRK3 Q16288 1/20 0.50
KDM4E B2RXH2 2/20 0.46
HTR5A P47898 1/20 0.46
NISCH Q9Y2I1 1/20 0.46
NR2E1 Q9Y466 1/20 0.46
MEN1 O00255 3/20 0.42
MAPT P10636 1/20 0.42
TSHR P16473 1/20 0.42
CRHBP P24387 1/20 0.42
MAPK1 P28482 1/20 0.42
CRHR2 Q13324 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6274438 0.91 LMNA (0.68) LMNAOPRM1OGFRL1OPRL1KMT2A
SCHEMBL998281 0.89 LMNA (0.94) LMNAOPRM1OGFRL1OPRL1KMT2A
SCHEMBL8323918 0.88 LMNA (0.97) LMNAOPRM1OGFRL1OPRL1KMT2A
SCHEMBL10051501 0.83 LMNA (0.69) LMNAOPRM1OGFRL1OPRL1KMT2A
SCHEMBL10051500 0.83 LMNA (0.69) LMNAOPRM1OGFRL1OPRL1KMT2A
SCHEMBL27016538 0.83 LMNA (0.69) LMNAOPRM1OGFRL1OPRL1KMT2A
SCHEMBL14500101 0.81 LMNA (0.66) LMNAOPRM1OGFRL1OPRL1KMT2A
SCHEMBL3564418 0.79 OPRM1 (0.77) LMNAOPRM1OGFRL1OPRL1KMT2A
SCHEMBL10038853 0.79 OPRM1 (1.00) LMNAOPRM1OGFRL1OPRL1
SCHEMBL517133 0.79 OPRM1 (1.00) LMNAOPRM1OGFRL1OPRL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240016775-A1 ANTI-CORONAVIRUS APPLICATION OF POLY ADP RIBOSE POLYMERASE INHIBITOR FUKANG (SHANGHAI) HEALTH TECHNOLOGY CO., LTD (CN) 2024-01-18 US disclosed
US-20230015617-A1 PHTHALAZINONE DERIVATIVES KUDOS PHARMACEUTICALS LIMITED (GB) 2023-01-19 US disclosed
US-11160803-B2 Phthalazinone derivatives KUDOS PHARMACEUTICALS LIMITED (GB) 2021-11-02 US disclosed
US-10449192-B2 Phthalazinone derivatives KUDO PHARMACEUTICALS LIMITED (GB) 2019-10-22 US disclosed
US-20180185363-A1 PHTHALAZINONE DERIVATIVES KUDOS PHARMACEUTICALS LIMITED (GB) 2018-07-05 US disclosed
US-20170226124-A1 PHTHALAZINONE DERIVATIVES KUDOS PHARMACEUTICALS LIMITED (GB) 2017-08-10 US disclosed
US-9566276-B2 Phthalazinone derivatives KUDOS PHARMACEUTICALS LIMITED (GB) 2017-02-14 US disclosed
US-20110015137-A1 RECA INHIBITORS AND THEIR USES AS MICROBIAL INHIBITORS OR POTENTIATORS OF ANTIBIOTIC ACTIVITY TRUSTEES OF BOSTON UNIVERSITY (US) 2011-01-20 US disclosed
WO-2004113336-A1 CARBOLINE AND BETACARBOLINE DERIVATIVES FOR USE AS HDAC ENZYME INHIBITORS CHROMA THERAPEUTICS LIMITED (GB) 2004-12-29 WO disclosed
WO-2004058263-A1 COMPOUND LIBRARIES OF 2, 3, 4, 9-TETRAHYDROSPIRO (BETA-CARBOLINE-1, 4 -PIPERIDINE) DERIVATIVES AND RELATED COMPOUNDS FOR TARGETTING COMPOUNDS CAPABLE OF BINDING TO THE G-PROTEIN RECEPTOR BIOFOCUS PLC (GB) 2004-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110015137-A1 RECA INHIBITORS AND THEIR USES AS MICROBIAL INHIBITORS OR POTENTIATORS OF ANTIBIOTIC ACTIVITY CGAS, RPIA, CLPP LMNA 1496/4885OPRM1 2863/4885OGFRL1 4240/4885
US-20170226124-A1 PHTHALAZINONE DERIVATIVES NR0B1, NR0B2, NR2E1 LMNA 2988/4885OPRM1 2057/4885OGFRL1 3380/4885
US-10449192-B2 Phthalazinone derivatives NR0B1, NR0B2, NR2E1 LMNA 2854/4885OPRM1 2205/4885OGFRL1 3569/4885
US-11160803-B2 Phthalazinone derivatives NR0B1, NR0B2, NR2E1 LMNA 2854/4885OPRM1 2205/4885OGFRL1 3569/4885
US-20240016775-A1 ANTI-CORONAVIRUS APPLICATION OF POLY ADP RIBOSE POLYMERASE INHIBITOR PARP3, PARP1, PARP4 LMNA 370/4885OPRM1 3967/4885OGFRL1 3688/4885
US-20230015617-A1 PHTHALAZINONE DERIVATIVES NR0B1, NR0B2, NR2E1 LMNA 2988/4885OPRM1 2057/4885OGFRL1 3380/4885
US-20180185363-A1 PHTHALAZINONE DERIVATIVES NR0B1, NR0B2, NR2E1 LMNA 2854/4885OPRM1 2205/4885OGFRL1 3569/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.